Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

References

• Vardiman JW, Thiele J, Arber DA, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437–438.
   PubMed Web of Science ®Google Scholar
• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372–375.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645–1651.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–2901.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007;109:68–76.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Barbui T, Di Gennaro L, The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007;136:249–259.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065–3072.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Barosi G, Elliot MA, Canepa L, Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301–2307.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534–2541.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771–775.
   PubMed Web of Science ®Google Scholar
• Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990;44:33–38.
   PubMed Web of Science ®Google Scholar
• Petti MC, Latagliata R, Spadea T, Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116:576–581.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361–370.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505–511.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Shrestha S, Sobocinski KA, Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358–367.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Shrestha S, Sobocinski KA, Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358–367.
   PubMed Web of Science ®Google Scholar
• el-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128–134.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications [see comments]. Blood 1999;93:417–424.
   PubMed Web of Science ®Google Scholar
• Ash RC, Detrick RA, Zanjani ED. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement. J Clin Invest 1982;69:1112–1118.
   PubMed Web of Science ®Google Scholar
• Dai CH, Krantz SB, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin–3. J Clin Invest 1991;87:391–396.
   PubMed Web of Science ®Google Scholar
• Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000;96:3310–3321.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788–22792.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Jelinek J, Oki Y, Gharibyan V, JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3373.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Dewald GW, Lasho TL, The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207–1209.
   PubMed Web of Science ®Google Scholar
• Scott LM, Campbell PJ, Baxter EJ, The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005;106:2920–2921.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Schwager SM, The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631–635.
   PubMed Web of Science ®Google Scholar
• Beer PA, Delhommeau F, LeCouedic JP, Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891–2900.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008;22:437–438.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med 2006;125:253–264.
   PubMedGoogle Scholar
• Campbell PJ, Griesshammer M, Dohner K, V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098–2100.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Specchia G, Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477–1483.
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL, Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279–2284.
   PubMed Web of Science ®Google Scholar
• Palandri F, Ottaviani E, Salmi F, JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma 2009;50:247–253.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703–1708.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952–1959.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Classification, diagnosis, and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240–245.
   PubMedGoogle Scholar
• Scott LM, Tong W, Levine RL, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960–1963.
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A, Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686–1689.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Levine RL, Lasho TL, MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472–3476.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128–1138.
   PubMed Web of Science ®Google Scholar
• Lasho TL, Pardanani A, McClure RF, Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006;135:683–687.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Pieri L, Bogani C, Constitutively activated and hyper-sensitive basophils in patients with polycythemia vera: role of JAK2V617F mutation and correlation with pruritus. Blood 2008;112(Suppl. 1): Abstract 3714.
   Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844–847.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289–2301.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lim KH, Abdel-Wahab O, Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343–1345.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Lim KH, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905–911.
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–1066.
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369–370.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24:1713–1718.
   PubMed Web of Science ®Google Scholar
• Sanada M, Suzuki T, Shih LY, Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904–908.
   PubMed Web of Science ®Google Scholar
• Loh ML, Sakai DS, Flotho C, Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009;114:1859–1863.
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27:6109–6116.
   PubMed Web of Science ®Google Scholar
• Grand FH, Hidalgo-Curtis CE, Ernst T, Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182–6192.
   PubMed Web of Science ®Google Scholar
• Jones AV, Chase A, Silver RT, JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446–449.
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Harutyunyan A, Jager R, A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450–454.
   PubMed Web of Science ®Google Scholar
• Carbuccia N, Murati A, Trouplin V, Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183–2186.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Roquain J, ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151: 365–375.
   PubMed Web of Science ®Google Scholar
• Jager R, Gisslinger H, Passamonti F, Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010;24:1290–1298.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24:1146–1151.
   PubMed Web of Science ®Google Scholar
• Ho K, Valdez F, Garcia R, Tirado CA. JAK2 translocations in hematological malignancies: review of the literature. J Assoc Genet Technol 2010;36:107–109.
   PubMedGoogle Scholar
• Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program 2010:115–121.
   PubMedGoogle Scholar
• Wernig G, Kharas MG, Okabe R, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311–320.
   PubMed Web of Science ®Google Scholar
• Ma L, Zhao B, Walgren R, Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Blood 2010;116(Suppl. 1): Abstract 4087.
   Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789–796.
   PubMed Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232–5240.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Deeg HJ, Odenike O, Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010;116(Suppl. 1): Abstract 3082.
   Google Scholar
• Santos FP, Kantarjian HM, Jain N, Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131–1136.
   PubMed Web of Science ®Google Scholar
• Shide K, Kameda T, Markovtsov V, Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2V617F-induced murine MPD model. Blood 2009;114(Suppl. 1): Abstract 3897.
   Google Scholar
• Purandare AV, Pardanani A, McDevitt T, Characterization of BMS-911543, a functionally selective small molecule inhibitor of JAK2. Blood 2010;116(Suppl. 1): Abstract 4112.
   Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 2010;116(Suppl. 1): Abstract 313.
   Google Scholar
• Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood 2008;112(Suppl. 1): Abstract 99.
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418–5424.
   PubMed Web of Science ®Google Scholar
• Ianotto J-C, Boyer-Perrard F, Demory J-L, Efficacy and safety of Peg-interferon-α2a in myelofibrosis: a study of the FIM and GEM French Cooperative Groups. Blood 2010;116(Suppl. 1): Abstract 4103.
   Google Scholar
• Vannucchi AM, Guglielmelli P, Lupo L, A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results. Blood 2010;116(Suppl. 1): Abstract 314.
   Google Scholar
• Mascarenhas J, Wang X, Rodriguez A, A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 2009;114(Suppl. 1): Abstract 308.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Salmoiraghi S, A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood 2008;112(Suppl. 1): Abstract 100.
   Google Scholar
• Mesa RA, Pardanani AD, Hussein K, Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129–130.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden. Blood 2010;116(Suppl. 1): Abstract 459.
   Google Scholar
• Hexner E, Goldberg JD, Prchal JT, A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood 2009;114(Suppl. 1): Abstract 754.
   Google Scholar
• Moliterno AR, Hexner E, Roboz GJ, An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood 2009;114(Suppl. 1): Abstract 753.
   PubMed Web of Science ®Google Scholar
• Pardanani A, George G, Lasho T, A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010;116(Suppl. 1): Abstract 460.
   Google Scholar
• Florensa L, Bellosillo B, Arenillas L, LY2784544, a novel JAK2 inhibitor, decreases in vitro growth of hematopoietic human progenitors from JAK2 V617F positive polycythemia vera patients. Blood 2010;116(Suppl. 1): Abstract 5054.
   PubMed Web of Science ®Google Scholar
• Shide K, Nakaya Y, Kameda T, NS-018, a potent novel JAK2 inhibitor, effectively treats murine MPN induced by the Janus Kinase 2 (JAK2) V617F mutant. Blood 2010;116(Suppl. 1): Abstract 4106.
   Google Scholar
• Nakaya Y, Naito H, Homan J, Preferential inhibition of an activated form of Janus Kinase 2 (JAK2) by a novel JAK2 inhibitor, NS-018. Blood 2010;116(Suppl. 1) Abstract: 4107.
   Google Scholar
• DeAngelo DJ, Tefferi A, Fiskus W, A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood 2010;116(Suppl. 1): Abstract 630.
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301–304.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Levine R, Manshouri T, Kilpivaara O, Kantarjian HM, Verstovsek S. High rates of molecular response after long-term follow-up of patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV) treated with pegylated interferon-alfa-2A (PEG-IFN-α- 2A; PEGASYS). Blood 2010;116(Suppl. 1): Abstract 461.
   Google Scholar